Answers are grounded in this paper and cite their sources.
Calpains, a family of Ca² + -activated proteases classically studied in cell-death pathways, are emerging as regulators of immune quiescence and tolerance, and may contribute to immune activation thresholds through distinct substrates including ZAP-70, NF-κB, and Cyclin D1. A systematic literature search according to PRISMA 2020 guidelines, which involved searching PubMed, Web of Science, Scopus, Google Scholar, and the Cochrane Library for records between 1990 and September 2026, was performed, and a total of 281 articles were recorded. Out of the total, 125 studies met inclusion criteria and were thus included in the review after a thorough title/abstract and full-text assessment. Across the included studies, calpains emerged as potential regulators of lymphocyte quiescence by acting on cell-cycle progression and T-cell receptor signaling pathways through proteolytic cleavage of Cyclin D1, and c-Myc, respectively. In addition, proposed regulation of checkpoint molecules such as PD-1 and CTLA-4 implicated calpain activity in immune self-tolerance, although direct cleavage evidence remains limited. Calpain dysregulation may contribute to immune suppression when proteolysis is excessive or to autoimmune disease when proteolysis is insufficient. In fact, preclinical data showed that pharmacological inhibition of calpains reduced the severity of autoimmune disease and inflammation; however, human efficacy data for calpain inhibition in autoimmune disease have not been established. Calpain dysregulation, irrespective of whether there is an increase or decrease in proteolysis, seems to cause diverse types of immune disorders, from immunosuppression to autoimmunity. This means that targeting calpains might be a possible therapeutic approach in autoimmune disease, chronic infections, and cancer.
No takes yet. Share an insight, caveat, or question.
Ahmad et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: